| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisals TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome and TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome. |
|
Medicine details |
|
| Medicine name | cannabidiol (Epidyolex®) |
| Formulation | 100 mg/ml oral solution |
| Reference number | 2589 |
| Indication | Adjunctive therapy of seizures associated with Lennox‑Gastaut syndrome or Dravet syndrome, in conjunction with clobazam, for patients 2 years of age and older |
| Company | GW Pharmaceuticals Plc |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 31/07/2019 |
| NICE guidance | TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome |